Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 58

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 58
---
 senior or equal in rank to the Series C Preferred Stock. As described below, the Required Holders of the Series C Preferred Stock consented to the issuance of the Series D Preferred Stock and Series E Preferred Stock, ranking pari passu therewith. Conversion Rights Conversion at Option of Holder.Each holder of Series C Preferred Stock may convert all, or any part, of the outstanding Series C Preferred Stock, at any time at such holder’s option, into shares of the Common Stock (which converted shares of Common Stock are referred to as “Series C Conversion Shares” herein) at a current “Series C Conversion Price” of $0.05 (following certain adjustments since the original issuance of such shares of Series C Preferred Stock), which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions. Alternate Conversion Upon a Triggering Event.Following the occurrence and during the continuance of a Series C Triggering Event (as defined below), each holder may alternatively elect to convert the Series C Preferred Stock at the “Series C Alternate Conversion Price” equal to the lesser of: •the Conversion Price, and •the greater of: •the floor price of $39.20 (originally $0.0196, but adjusted for the 1 for 100 reverse stock split effected on January8, 2025 and for the 1 for 20 reverse stock split effected on June13, 2025); and •80% of the volume weighted average price of the Common Stock during the 5 consecutive trading days immediately prior to such conversion. The Series C Certificate of Designations contains standard and customary triggering events (each, a “Series C Triggering Event”), including but not limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S -1pursuant to the Registration Rights Agreement, dated as of September 25, 2024, by and between the Company and the holders of Series A Preferred Stock party thereto (the “Second Registration Rights Agreement”), (iv) our failure to cure a conversion failure of failure to deliver shares of the Common Stock under the Series C Warrants, or notice of our intention not to comply with a request for conversion of any Series C Preferred Stock or a request for exercise of any Series C Warrants, and (iv) bankruptcy or ins